50 related articles for article (PubMed ID: 34979750)
41. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS; Nagasaka M; Zhu VW; Ou SI
Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
[TBL] [Abstract][Full Text] [Related]
42. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review.
Iannantuono GM; Riondino S; Sganga S; Roselli M; Torino F
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409355
[TBL] [Abstract][Full Text] [Related]
43. ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature.
Galea LA; Hildebrand MS; Witkowski T; Joy C; McEvoy CR; Hanegbi U; Aga A
Virchows Arch; 2023 Mar; 482(3):625-633. PubMed ID: 36370168
[TBL] [Abstract][Full Text] [Related]
44. Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.
Chopra S; Maloney N; Wang WL
Brain Tumor Pathol; 2022 Jan; 39(1):35-42. PubMed ID: 34743247
[TBL] [Abstract][Full Text] [Related]
45. ALK-Positive Histiocytosis: A Case Report and Literature Review.
Jaber OI; Jarrah DA; Hiasat M; Hussaini MA
Turk Patoloji Derg; 2021; 37(2):172-177. PubMed ID: 33973641
[TBL] [Abstract][Full Text] [Related]
46. [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis].
Di SH; Wang XT; Xia QY; Lu ZF; Ma HH; Zhang RS; Wang X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):28-32. PubMed ID: 34979750
[No Abstract] [Full Text] [Related]
47.
Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
[TBL] [Abstract][Full Text] [Related]
48. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
49. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
[TBL] [Abstract][Full Text] [Related]
50. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]